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ABSTRACT: Human Chronic Myelogenous Leukemia (CML) is a malignancy of pluripotent 
hematopoietic cells characterized by distinctive cytogenetic abnormality known as the Philadelphia 
(Ph) chromosome, which resulted in the creation of a p210 Bcr-Abl fusion protein with increased tyrosine 
kinase activity. Forty-two species of Higher Basidiomycetes mushrooms were cultivated as pure 
cultures in submerged conditions, and dry mycelium were used to prepare 168 different crude extracts. 
The crude extracts were used to evaluate anti-proliferative activity against a number of cancer cell 
lines, including K562 (Human Chronic myelogenous leukemia cell line), Jurkat (human T lymphoblast 
cells), HT29 (human colon adenocarcinoma cells), MH3924A (rat Morris hepatoma), and ABAE (adult 
bovine aortic endothelial cells) using XTT proliferation assay. Forty-four different crude extracts were 
selected with anti-proliferative effect against K562 cells and eight mycelium extracts were K562-
selective compared with MH3924A, HT29, ABAE, and Jurkat cells. Growth inhibition against K562 
ranged from 51% to 78% compared with solvent-treated samples. Most crude extracts exhibited a 
complete or partial cytostatic effect against K562 cells. The anti-proliferative effect observed by the 
selected crude extracts was attributed to the induction of apoptosis pathway as determined by Apostain 
ELISA assay and by monitoring PARP cleavage. Interestingly, crude extract MH428 was the most 
active extract in inducing apoptosis of K562 cells. In addition, expression levels of p210 Bcr-Abl were 
affected by the presence of the selected crude extracts. Our data revealed a significant inhibition of 
p210 
Bcr-Abl
 expression by MH428 extract, a moderate effect by MH17, and minor changes by the other 
extracts. Furthermore, mycelium crude extracts were active in inducing erythroid differentiation in 
K562 cells. Crude extracts Meth178, MH17, and MH428 show significant ability to induce hemoglobin 
production in K562 cells as indicative of erythroid differentiation. The results obtained support the 
potential use of the crude mycelium extracts for the treatment of CML and beta-globin disorders. 
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Higher Basidiomycetes mushrooms (HBM) represent a major and still largely untapped source of 
potent new pharmaceutical products. Of approximately 15,000 known species, 2,000 are safe for 
human consumption, and about 650 of them possess medicinal properties (Wasser et al., 2000; 
Hawksworth, 2001; Kirk et al., 2001; Wasser, 2002). Of about 650 mushroom species with known 
medicinal properties, only about 20 species are in use at the present (Chang, 2001). Most traditional 
knowledge about medicinal properties of HBM comes from the Far East (China, Japan, Korea, Russian 
Siberia). Many pharmaceutical substances with potent and unique properties have recently been 
extracted from mushrooms and have made their way all around the world. Unique anticancer medicines 
were prepared from these extracts such as polysaccharides Lentinan, Krestin, and  Schizophyllan 
(Mizuno, 1999). 
 
Present studies suggest that HBM are probiotic - they help the body to strengthen itself and fight off 
illness by maintaining physiological homeostasis, restoring the body’s balance and natural resistance to 
disease. The compounds they contain have been classified as Host Defense Potentiators (HDP), which 
can have immune system enhancement properties. That is one of the reasons why they are currently 
used as adjuncts to cancer treatments in many countries (Tomatis et al., 2001). In Japan, Russia, China, 
and the U.S.A. several different polysaccharide anticancer and immunomodulating agents have been 
developed from the fruiting body, mycelia, and culture medium of various medicinal mushrooms 
(Lentinus edodes, Ganoderma lucidum, Schizophyllum commune, Trametes versicolor, Inonotus 
obliquus, Hypsizygus marmoreus, and Flammulina velutipes) (Ikekawa, 2001).  
 
Mushrooms` HDP include hemicellulose (AHCC), polysaccharides, polysaccharide -peptides, 
nucleosides, triterpeniods, complex starches, and other metabolites. It is believed that combinations of 
these products target the human immune system, and also aid neuron transmission, metabolism, 
hormonal balance, and the transport of nutrients and oxygen. Through a host-mediated (T cell) immune 
mechanism, they help the body regulate the development of lymphoid stem cells and other important 
defense responses (Mizuno, 1999). 
Chronic myelogenous leukemia (CML) is a member of a group of diseases classified as 
myeloproliferative disorders, which account for 20% of all leukemias. CML is a clonal disorder that is 
usually
 
easily recognized because the leukemia cells of more than 95%
 
of patients suffering from CML 
have a distinctive cytogenetic abnormality, the Philadelphia chromosome. This results from a reciprocal 
translocation between the long arms of chromosomes 9 and 22. This translocation results in the transfer 
of the Abelson (Abl) oncogene on chromosome 9 to an area of chromosome 22 that includes the 
breakpoint cluster region (bcr) gene. This results
 
in the presentation of a leukemia-specific fusion gene 
(bcr-Abl) which gives rise to an abnormal tyrosine kinase protein, p210, with increased activity 
(Clarkson et al., 1997; Cortez et al., 1997). Bcr-Abl expressing leukemic blasts are highly resistant to 
different classes of chemotherapeutic drugs. K562 cells, derived from patients with CML in blast crisis 
(Lozzio and Lozzio, 1975), which express p210 
Bcr-Abl
, have been shown to be highly resistant to 
apoptosis induced by many chemotherapeutic agents (McGahon et al., 1994). Over-expression of Bcr-
Abl has been implicated in inhibiting apoptosis induced by cytokine deprivation, DNA damage, and a 
variety of chemotherapeutic drugs (Cortez et al., 1997). Thus, the Bcr-Abl fusion protein has been 
suggested to function as an antiapoptotic factor and over-expression of the Bcr-Abl protein in K562 
cells may, in part, account for the resistance of these cells to apoptosis, thereby leading to the 
accumulation of leukemic blasts in patients with chronic myeloid leukemia (Urbano et al., 1998).   
Apoptosis, programmed cell death, is a genetically controlled ablation of cells during development. It is 
characterized by chromatin condensation, nuclear fragmentation, cell membrane blebbing, apoptotic 
body formation, and mitochondrial changes including enhanced membrane permeability, fall of 
mitochondrial membrane potential ( m) and release of cytochrome c into the cytosol. Induction of 
apoptosis is the principal mechanism by which the majority of chemotherapeutic agents exert their 
function. Consequently, failure to undergo apoptosis is the likely mechanism mediating drug resistance 
in tumors.  
Although most bioactive substances isolated from mushrooms have been high-molecular- weight 
(HMW) polysaccharides, our interest is in low-molecular-weight (LMW) compounds capable of 
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exhibiting antitumor activity. In this study, we focused on the search for novel compounds that induce 
apoptosis in chronic myelogenous leukemia  cells that might be useful in the therapy of patients with 
CML. We succeeded in identifying mycelium crude extracts that selectively inhibit the growth, 
promote apoptosis, and induce erythroid differentiation of K562 cells. 
 
MATERIALS AND METHODS 
 
Mushroom Species, Cultivation and Extraction  
The strains used in our investigation are from a Culture Collection of HBM (acronym HAI) of Haifa 
University (Wasser et al., 2002) (presently over 1000 strains of edible and medicinal mushrooms). 
About 200 species were collected in different ecological regions of Israel, and new strains have been 
permanently introduced into the collection. The collection also contains many diverse strains of well-
known medicinal mushrooms from North America, Europe, and other parts of  the world. Table 1 
shows a list of mushroom species used to prepare the mycelium crude extracts. Mushrooms were 
grown initially in agar plates at 27 ˚C, and then transferred to liquid media to generate a starter culture. 
Large-scale growth was carried out in 500 mls liquid medium in 2 liters Erlenmeyer for 2-3 weeks at 
27 ˚C with shaking at 180 rpm.  
 
TABLE 1 
List of Mushroom Species Used in This Study and Yield of Various Crude Extracts Prepared 
From Mycelium of Submerged Cultures 
 
  mg of crude extract / gram of dry mycelium 
Species, authors HAI 
strain 
number 
C E H Eth 
1 Trametes zonata (Nees.:Fr.) 
Pilat 
540 183 64 16 110 
2 T. multicolor (Schaeff.) 
Jülich 
428 100 90 70 50 
3 T. hirsutus (Wulf.:Fr.) Pilat 598 376 340 462 418 
4 Hypsizygus ulmarium 
(Bull.:Fr.) Redhead 
812 55 88 107 96 
5 H. decastes (Fr.) Sing   510 117 107 93 107 
6 H. marmoreus (Peck) Bigel. 
  
609 144 91 82 96 
7 Panus conhatus (Bull.:Fr.) 
Fr. 
396 100 100 100 80 
8 Ganoderma adspersum (S. 
Schulz.) Donk 
349 245 100 230 180 
9 G. applanatus (Pers.: Wallr.) 
Pat.  
604 210 160 200 215 
10 G. resinaceum Boud.   142 220 170 210 220 
11 Piptoporus betulinus 
(Bull.:Fr.) P. Karst. 
241 240 ND 200 ND 
12 Omphalotus olearius 
(DC.:Fr.) Fr.   
173 110 100 115 140 
13 Pleurotus eryngii (DC.:Fr.) 
Quel. 
202 156 131 169 100 
14 P. ostreatus (Jacq.:Fr.) 
Kumm. 
592 200 80 70 100 
15 P. salignus (Fr.) Kumm.   571 75 44 75 69 
16 P. cystidiosus O.K. Miller 140 169 146 133 108 
17 P. pulmonarius (Fr.) Quel. 
  
573 169 108 75 116 
18 Kuehneromyces mutabilis 114 100 70 100 120 
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(Schaeff.:Fr.) Singer et A.H. 
Sm. 
19 Rigidoporus ulmarius (Sow.: 
Fr.) Imazeki 
439 60 60 70 60 
20 Spongipellis litshaueri 
Lohw. 
444 100 100 60 100 
21 Panellus stipticus (Bull.:Fr.) 
P. Karst. 
520 100 90 90 70 
22 P. serotinus (Pers.:Fr.) 
Kühn.   
498 169 119 125 156 
23 Gloeophyllum odoratum 
(Wulf.) Imazeki  
337 100 70 90 90 
24 Schizophyllum commune Fr.: 
Fr.    
632 90 60 80 50 
25 Oudemansiella radicata 
(Relh.:Fr.) Singer 
773 170 130 180 150 
26 O. mucida (Schrad.:Fr.) 
Hoehn. 
181 170 100 140 130 
27 Leucoagaricus carneifolius 
(Gill.) S. Wasser 
344 110 65 100 98 
28 L. leucothitus (Vitt.) S. 
Wasser   
282 185 160 155 160 
29 Marasmius scorodonius 
(Fr.) Fr.   
784 290 160 70 150 
30 Polyporus squamous 
Huds.:Fr.   
242 180 75 140 80 
31 Pholiota aurivella 
(Batsch:Fr.) Kumm. 
236 125 80 65 88 
32 Grifola frondosa (Dicks.:Fr.) 
S. F. Gray   
270 173 152 193 133 
33 Fomes fomentarius (L.:Fr.) 
Fr.   
383 163 138 63 125 
34 Lentinus edodes (Berk.) 
Singer    
313 187 193 200 207 
35 Phellinus ignarius (L.:Fr.) 
Quel.   
785 131 113 138 103 
36 Merulius tremellosus Fr.   267 286 120 320 ND 
37 Irpex lacteus (Fr.:Fr.) Fr.   532 178 168 176 152 
38 Inonotus levis P. Karst.   796 174 144 115 118 
39 Flammulina velutipes 
(Curt.:Fr.) Singer   
105 153 64 125 58 
40 Oxyporus obducens (Fr.) 
Donk   
824 97 95 109 108 
41 Agaricus langei (Moell.) 
Moell.  
295 88 102 46 86 
42 Funalia trogii (Berk. upud. 
Trog.) Bond. et Singer 
352 200 130 150 60 
Medicinal mushrooms were grown in submerged condition and mycelium was dried and used to prepare crude 
extracts using various mixtures of organic solvents including Eth (70% ethanol), E (33% ethyl acetate, 50% 
methanol), H (22% ethyl acetate, 11% methanol), and C  (33% chloroform, 50% methanol). Obtained yield of 
crude extract with the various mixtures of organic solvents is shown in mg/gram of dried mycelium used. Nd 
indicates not determined. 
  
Mushroom Growth Medium 
Mushrooms were grown in liquid or solid media containing 2% glucose, 0.1% bacteriological peptone, 
0.1% yeast extract, 0.1% KH2PO4, 0.1% MgSO4, and 1.7% of a Bacto-Agar in agar plates. The media 
were also supplemented with 10mls per 1 liter of trace solution (18mM FeSO4, 3.7mM MnSO4, 1.5mM 
ZnSO4, 0.8mM CuSO4).  
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Preparation of Mycelium Crude Extracts 
Dry mycelium was extracted with four different solvents (1 gram of material used 
 for each condition) as shown in Table 2:  
 
TABLE 2 
Extract Symbol and Composition of Solvents 
Extraction method symbol Composition of solvents 
C 50% Methanol, 33% Chloroform 
E 50% Methanol, 33% Ethyl acetate 
H 22% Ethyl acetate, 11% Methanol  
Eth 70% Ethanol  
 
 
Cell Lines and Cell Culture 
Human K562, Jurkat, and HT-29 cell lines were grown in RPMI 1640 with L-glutamine supplemented 
with 10% fetal bovine serum. ABAE, Bovine aortic arch-derived endothelial cell (ABAE) and 
MH3924A were grown in DMEM and supplemented with 10% fetal bovine serum. Penicillin at 100 
U/ml and Streptomycin at 100 µg/ml were added to the culture media. All cell lines were grown at 37 
°C  in a humidified atmosphere with 5% CO2. Adherent cell lines were transferred with 0.025% trypsin 
and 0.02% EDTA. 
 
Cell Viability 




cells/ml) in triplicate were incubated 
in 2 ml of RPMI 1640–10% FCS containing mycelium crude extracts or DMSO. The volume of the 
DMSO was kept at 0.6% of the medium volume. At the indicated times, cell viability was determined 
by the trypan blue exclusion assay (Freshney, 1987).  At least 200 cells were examined in each sample. 
Data were expressed as % inhibition relative to solvent-treated samples. 
 
Erythroid Differentiation 
Erythroid differentiation was determined by monitoring levels of hemoglobin production in treated 




) cells/ml, followed by treatment with various 
concentrations of mycelium extracts for 5 days. Cells were washed with phosphate-buffered saline 
(PBS) and cell pellet was  re-suspended in 100 µL lysis buffer (100 mM potassium phosphate pH 7.8, 
0.2% Triton x-100) and incubated for 10 min at room temperature. Intracellular hemoglobin levels 
were determined by means of the plasma hemoglobin kit from Sigma according to the manufacturer's 
instructions (Sigma, USA). Levels of hemoglobin were normalized to protein concentration found in 
each sample. Protein concentration was determined by DC protein Assay Kit (Bio-Rad, USA) 
according to manufacturer’s instructions. Relative hemoglobin levels were calculated in relation to 
solvent-treated sample, which was designated 1.  
 
XTT Cell Proliferation Assay   
XTT assay is based on the MTT assay (Mosmann, 1983) used to monitor cell proliferation growing in 
suspension. In brief, K562 cells were seeded in 96 well plates at 1.5x 104 cells/well; 24 hours later cells 
were treated with mycelium crude extracts at 1 mg/ml and 250 µg/ml for an additional 24 hours. 50 µL 
of XTT solution at 1.5 µg/ml were added to each well and were incubated for three hours at 37 °C. The 
optical density was measured by multi-well plate spectrophotometer at 405 nanometers. 
PARP Cleavage   
To analyze PARP cleavage (Dou et al., 1999), cells (2 x 105 cells/ml) were treated with mycelium 
crude extracts or DMSO for the indicated time. Cells were collected, washed once with cold PBS, and 
lysed in buffer [10 mM Tris-HCl (pH 7.4), 100 mM NaCl, 1 mM EDTA, 1mM EGTA, 1mM NaF, 20 
mM Na4P2O7, 2 mM Na3VO4, 1% Triton x-100, 10% Glycerol, 0.1% SDS,  0.5% deoxycholate, 1 mM 
phenylmethylsulfonyl fluoride] for 30 min at 4 °C. Cell lysate supernatants (40 µg protein/each) were 
resolved on 8% SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose membranes, and 
analyzed by immune-blotting with an anti-PARP antibody (Santa Cruz Co., USA).  
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Apostain ELISA Assay  
K562 cells (1x105 cells/ml) were treated with mycelium crude extracts or DMSO for 48 hr.  Samples 
were collected, washed with PBS, and re-suspended in 100 µl of 80% methanol, and kept at –20 °C  for 
2-3 days. Between 2500 and 5000 cells were used for Apostain ELISA assay according to 










Identification of Selective K562 Mycelium Crude Extracts 
A large number of medicinal mushrooms shown in Table 1 were cultivated in submerged conditions 
and extracted with various extraction solvents, as described in Materials and Methods, resulting in the 
preparation of 168 crude mycelium extracts. Crude extracts were screened for their ability to inhibit the 
growth of K562, a human chronic myelogenous leukemia blast cell. Growth inhibition was evaluated 
by XTT assay as described in Materials and Methods.  
 
Cleavage of the tetrazolium salt XTT, sodium 3'-[1-[(phenylamino)-carbonyl]-3,4-tetrazolium]-bis(4-
methoxy-6- nitro)benzene-sulfonic acid hydrate by dehydrogenase enzymes of metabolically active 
cells yields a highly colored formazan product, which is water soluble. This feature obviates the need 
for formazan crystal solubilization prior to absorbance measurements, as required with the use of other 
tetrazolium salts such as MTT, and offers a simple method for evaluating proliferation of cells growing 
in suspension such as K562 cells (Roehm et al., 1991). 
 
Anti-proliferative activity of crude mycelium extracts were evaluated against K562 cells and obtained 
results are summarized in Table 3.  A total of 44 crude extracts from the 168-screened extracts were 
active in inhibiting the growth of K562 cells by more than 50%. The 44 crude mycelium extracts 
represent about 26% of the screened extracts. The number of active extracts among the various 
extraction methods varied significantly. With solvent mixtures H (22% ethyl acetate, 11% methanol), 
E (33% ethyl acetate, 50% methanol), C (33% chloroform, 50% methanol), and Eth (70% ethanol), 
the number of K562 active extracts were 5, 13, 12, and 14, respectively (Table 3).  
 
TABLE 3 
Distribution of K562 Active Mycelium Crude Extracts Among the Different  
Organic Mixtures  
   Number                           %    
Extracts Total H E C Eth Total H E C Eth 
Screened  168 41 43 42 42 100 24.4 25.6 25 25
  
Active (>50%) 44 5 13 12 14 26 11.4 29.5 27.3 31.8 
Selective 8 4 0 1 3 18.2 50 0 12.5 37.5 
K562 cells were plated in 96 well plates at 1.5x104 cells/well and 24 hours later were treated with mycelium crude 
extracts at 250 µg/ml and 1mg/ml (with addition of 10 µl of stock solution to each well containing 100 µl of K562 
cells). Twenty-four hours later XTT assay was performed as described in Materials and Methods.  
 
The K562 active crude extracts were subjected to selectivity evaluation by monitoring growth 
inhibition of the selected extracts against other cell lines, including Jurkat (human T lymphoblast), 
HT29 (human colon adenocarcinoma cells), MH3924A (rat Morris hepatoma), and ABAE (adult 
bovine aortic endothelial cells). Mycelium crude extracts that inhibited K562 by more than 50% and 
showed minimal growth inhibition (less than 30% inhibition) against other cell lines were designated 
as selective K562 inhibitors (Table 4). Table 4 shows a list of selective mycelium crude extracts with 
percentage of growth inhibition applied to a variety of cell lines. Growth inhibition was calculated 
compared with solvent-treated samples. 
 
TABLE 4 
The Effect of K562-Selective Mycelium Crude Extracts on the Growth of K562, MH3924A, 
ABAE, HT-29 and Jurkat Cell Lines  
                                                 %  of Growth Inhibition     
Ext Mushroom  Strain  Solvent K562  MH3924A ABAE  HT-29 Jurkat  
MH161 Kuehneromyces mutabilis  114 H 61.3  16.6  -30.1 -19.5  16.2 
MH210 Pleurotus eryngii    202 H 53.8    3.4  -34.0 -27.2    8.8 
Meth178Omphalotus olearius 173 Eth 56.9 -14.5  -56.2 -11.3 -36.4 
MH17 Piptoporus betulinus  241 H 68.8  15.2   28.2   -7.6   -2.9 
Meth134 Ganoderma adspersum  349 Eth 59.2 -15.5  -44.7  23.1 -18.4 
Meth114 Panus conchatus       396 Eth 56.0  11.5   27.8    4.3    2.4 
MC293 Hypsizygus ulmarium          812 C 56.7  14.4  -28.9  -7.6    7.3 
MH428 Trametes zonata                 540 H 69.0 -11.4   -5.1   1.9  30.1 
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Cells were plated in 96 well plates at 1.5x104 cells/well. Twenty-four hours later mycelium crude 
extracts were added for an additional 24 hours followed by XTT determination according to 
manufacturer’s instructions (Biological Industries, Israel). Percentage of growth inhibition was 
calculated in relation to solvent-treated samples. Experiments were carried out in duplicate. Changes in 
%CV among duplicate samples were minimal. For example %CV in growth inhibition of K562 using 
duplicate samples treated with mycelium crude extracts MH161, MH210, Meth178, MH17, Meth134, 
Meth114, MC293, MH428 were 0.4, 28, 6.4, 1.1, 4.3, 1.9, 17.9, 4.1, respectively.  This experiment was 
repeated twice with similar outcomes. 
 
Tables 3 and 4 show that a total of 8 mycelium crude extracts exhibited selective activity against K562 
cells. The 8 positive crude extracts were distributed among the various extraction methods as follows: 
4, 0, 1, and 3 using organic mixture H, E, C, and Eth, respectively. Interestingly, most of the selective 
extracts were extracted by means of the H and Eth organic mixtures.   
 
It is important to note that XTT assay does not distinguish between cytostatic and cytotoxic effects in 
continuously proliferating cultures. Therefore, the effect of the selected mycelium crude extracts on the 
viability of K562 cells was evaluated. Although cell viability can be reflected by a variety of different 
parameters, integrity of the outer cell membrane is often used. The vital dye trypan blue, which is 
usually excluded from viable cells, was used to assess whether mycelium crude extracts function as a 
cytotoxic or a cytostatic compound against K562 cells. Cells were treated with 500µg/ml of the 





























FIGURE 1. Effect of mycelium crude extracts on the viability of K562 cells.  
K562 cells were plated in 6 well plates at 1x10
5
 cells/ml (Day –1). Twenty-four hours later (Day 0) 
500µg/ml of mycelium crude extracts Meth114, MH428, MC293, MH161, Meth178, MH210, MH17, 
and Meth134 (see Table 4 for mushroom species) were added and cell numbers were monitored for 4 
days by trypan blue exclusion assay as described in Materials and Methods. Experiments were carried 
out in duplicate. Changes in duplicate samples were minimal with % CV below 10% in all 
experiments. This experiment was repeated twice with similar outcomes. 
   
Data presented in Figure 1 illustrate that most mycelium crude extracts exhibit a complete (MH210, 
Meth134, Meth114, MH326) or partial (Meth178, MH17, MC293) cytostatic effect. In contrast, crude 
extract MH161 exhibited cytotoxic effect at the concentration used.   
 
Involvement of the Apoptosis Pathway in Mediating the Growth Inhibition of K562 Cells by 
Mycelium Crude Extracts  
Apoptosis, programmed cell death, is a genetically controlled ablation of cells during development. 
Furthermore, induction of apoptosis is the principal mechanism by which the majority of 
chemotherapeutic agents exercise their function. Accordingly, we evaluated whether our mycelium 
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crude extracts affected the apoptosis pathway in K562 cells. Our data show that 8 mycelium crude 
extracts exhibited selective anti-proliferative effect against K562 cells as determined by XTT assay 
(Table 4) and trypan blue exclusion assay (Figure 1).  
 
To evaluate whether the anti-proliferative effect of mycelium crude extracts is mediated by induction 
of the apoptosis process, we monitored changes in chromatin condensation as a marker of apoptosis 
(Allera et al., 1997). A recent report illustrated that formamide, a gentle denaturing agent, denatured 
DNA in apoptotic cells, but not in necrotic cells (Frankfurt and Krishan, 2001a,b). Apostain ELISA kit 
(Alexis Biochemicals, USA) utilizes the increased sensitivity of DNA in condensed chromatin of 
apoptotic cells to denaturation by formamide (Frankfurt and Krishan, 2001a), which is attributed, in 
part, to changes in the DNA-histone interactions. The increased sensitivity of cells with denatured 
DNA is detected by a monoclonal antibody specific for single-strand DNA (Mab F7-26) in an ELISA 
format (Frankfurt and Krishan, 2001b).  
 
K562 cells were treated with the appropriate mycelium crude extracts and samples were collected 48 
hours post treatments. Apostain ELISA assay was performed according to manufacturer’s instructions 
and as detailed in Materials and Methods. Data shown  (Table 5) illustrate the ability of the various 
mycelium crude extracts to induce an increase in DNA condensation. Almost all crude extracts were 
able to induce a more than twofold increase in DNA condensation above the solvent-treated sample. 
Mycelium crude extracts Meth178, MH17, Meth134, MC293, and MH428 induced increases in DNA 
condensation to values of 4.3, 3.5 3.6, 5.3, and 2.8, respectively, after 48-hr. treatments.     
 
Furthermore, AG957, a known p210 Bcr-Abl inhibitor (Kaur et al., 1994), also significantly induced an 
increase in DNA condensation at 10µM.  Interestingly, a higher dose of mycelium crude extracts 
caused a decrease in the measured signal, suggesting that at higher concentrations of mycelium 
extracts, cell death is mediated, in part, by necrosis.   
 
TABLE 5 
Apostain Values from K562 Cells treated With Mycelium Crude Extracts  
 
Mycelium Extract  Relative Apostain Value   
250µg/ml   500µg/ml 
MH210    1.9      1.9 
Meth178   4.3      1.4    
MH17    3.5      1.6 
Meth134   3.6      3.2 
MC293    5.3      6.5 
MH428    2.8    10.9 
 
AG957   6.2 (10 µM)     3.9 (20 µM)   
K562 cells were plated in 6 well plates at 1x105 cells/ml. Twenty-four hours later cells were treated with mycelium 
crude extracts at 250 µg/ml and 500 µg/ml (see Table 4). The tyrphostin AG957 at 10 µM and 20 µM was 
included as a positive control. In addition, a solvent-treated sample was  included, in which DMSO was added to 
0.6%. Forty-eight hours post treatment cells were counted and washed with cold PBS and subjected to Apostain 
ELISA Assay according to manufacturer’s instruction. To calculate relative Apostain values, empty wells were 
subtracted from absorbance values obtained from cells treated with the different extracts. The solvent-treated 
sample was assigned as 1, and relative values were calculated. 
 
The execution of apoptosis requires specific molecular machinery, the central component of which is a 
family of proteases called caspases. Caspases are cysteine proteases that cleave proteins after specific 
aspartate residues, in response to proapoptotic signals (Nicholson and Thornberry, 1997). During 
apoptosis, caspases activated in an amplifying proteolytic cascade, cleave one another in sequence 
(Raff, 1998). One of the most widely studied caspases, caspase 3, is classified as an effector caspase 
and cleaves death substrates such as the structural protein lamin and the nuclear protein poly (ADP-
ribose) polymerase (PARP) (McGowan et al., 1996). K562 cells treated with the appropriate 
concentration of mycelium extracts were used to monitor cleavage of poly (ADP-ribose) polymerase 
(PARP) as an indication of the activation of the apoptosis pathway.  K562 cells were treated with the 
appropriate mycelium  extracts for 48 hours. Presence of cleaved PARP was monitored by means of 
anti-PARP. Treatment with AG957, a known Bcr-Abl inhibitor (Kaur et al., 1994), significantly 
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activates PARP cleavage, attesting that AG957 promotes apoptosis in K562 cells. Although most 
mycelium extracts shown (Figure 2) failed to activate cleavage of PARP, extract MH428 significantly 










FIGURE 2. Cleavage of PARP  by mushroom extracts. 
 K562 cells were plated in T25 flasks at 1x10
5 
cells /ml. Twenty-four hours later mycelium crude 
extracts MC293, MH428, tyrphostin AG957 (part A), MH210, Meth178, MH17, and Meth134 (part B) 
were added at 500µg/ml and 250µg/ml for 48 hours. Cell lysates were resolved into 8% SDS-
polyacrylamide gel  electrophoresis followed by transfer to nitrocellulose filters. Western Blotting was 
performed as described in Materials and Methods in which monoclonal anti-PARP antibody was used 
(Santa Cruz Co., USA).  
 
Mycelium Crude Extracts Induce Terminal Differentiation of K562 Cells 
 
Leukemic blasts expressing p210 Bcr-Abl display arrested differentiation, as well as resistance to 
apoptosis, even when exposed to high doses of anti-leukemic drugs (Bedi et al., 1995; Ray et al., 
1996). K562 is a human erythroleukemia cell line derived from a patient with chronic myelogenous 
leukemia (Lozzio and Lozzio, 1975). These cells are pluripotent in that they are able to differentiate 
along a megakaryocytic, erythroid, or, to a lesser extent, monocytic lineage (Leary et al., 1987). 
Erythroid differentiation can be induced by a number of compounds, including hemin and butyric acid 
(Rowley et al., 1981). However, TPA (or PMA) treatment induces macrophage-like morphology and 
promotes the expression of proteins associated with megakaryocytes (Leary et al., 1987; Burger et al., 
1992).  Erythroid differentiation is frequently monitored by induced expression of hemoglobin, while 
megakaryocyte differentiation can be assessed by monitoring of the ability of treated K562 cells to 
reduce NBT (Sutherland et al., 1986).  
 
To assess erythroid differentiation, we monitored levels of hemoglobin production in treated cells 
using a commercially available kit (Sigma, USA). Levels of expressed hemoglobin assayed at Day 5 
post-treatment were normalized to the amount of total proteins present in each sample.  Relative units 
of hemoglobin were calculated in relation to levels of hemoglobin found in solvent-treated samples 
(DMSO at 0.6%). Results summarized in Table 6 show that butyric acid was active in inducing 
hemoglobin expression in K562, which is in agreement with published data (Villeval et al., 1983). 
Furthermore, three mycelium crude extracts were active in inducing hemoglobin expression above the 
levels of DMSO-treated cells. Extracts MH17 and MH428 induced hemoglobin expression 
respectively 4.2 and 2.1 times higher than  the solvent-treated cells. Interestingly, extract Meth178 was 
the most potent extract (about 12 times higher than DMSO-treated cells) and was more active than 




Induction of Hemoglobin Expression in K562 cells by Mycelium Crude Extracts 
Mushroom  Strain Extract   Concentration             Relative  
Species        (µg/ml)              Hemoglobin 
---------------------------------------------------------------------------------------------------- 
Kuehneromyces mutabilis  114 MH161  300   0.9 
Pleurotus eryngii    202 MH210  500   0.8 
Omphalotus olearius 173 Meth178 500               11.9 
Piptoporus betulinus  241 MH17  500   4.2 
Ganoderma adspersum  349 Meth134 500   0.7 
Panus conchatus                396 Meth114 300   0.2 
Hypsizygus ulmarium  812 MC293  300   0.8 
Trametes zonata   540 MH428  250   2.1 
 
Butyric Acid               1mM   9.4 
__________________________________________________________________________ 
 
K562 cells were plated at 2x105 cell/ml in 6 well plates. Twenty-four hours later mycelium crude extracts at 
appropriate concentration were added. Growth of K562 cells in the presence of crude extracts was monitored by 
trypan blue exclusion assays as described in Materials and Methods. Numbers of viable cells were monitored after 
2 and 4 days post treatment. On Day 5, cells were washed with PBS, cell pellet was lysed, and levels of 
hemoglobin were determined as described in Materials and Methods. Hemoglobin levels were normalized to 
protein concentration in each sample. Relative hemoglobin levels were calculated in relation to solvent-treated 
sample, which was designated 1.0. The experiment was carried out in duplicate with minimal variations. This 
experiment was repeated twice with similar outcomes. 
 
Involvement of MAP Kinase p38 in Mediating Growth Inhibition of Mycelium Crude Extracts 
 
Previous reports indicated that proliferation and differentiation of K562 cells are mediated by mitogen-
activated protein kinase (MAPK) pathway (Cobb, 1999; Cross et al., 2000). We examine the 
involvement of MAPK p38 in mediating the anti-proliferative effect of mycelium crude extracts.  This 
was achieved by pretreatment of K562 cells with SB203580, selective inhibitors of p38, in the 
presence of the various mycelium crude extracts.  
 
Data shown in Table 7 indicate that pretreatment of SB203580 resulted in a moderate relief of the 
growth inhibition caused by MH161, Meth178, and MH210 and no influence in MC293 and MH428 
extracts. These results indicate that anti-proliferative function of Meth114, MH161, Meth178, MH17, 
and MH210 are partially dependent on p38. Furthermore, p38 kinase pathway is not involved in 
mediating the anti-proliferative effect of mycelium extracts MC293 and MH428.  
 
TABLE 7  
Involvement of MAP Kinase p38 in the Growth Inhibition of K562 Cells by Mycelium Crude 
Extracts  
 
Extract  Strain  Inhibition of K562    
     -  SB203580 (10µM)  
Meth114 396  56   27.9  
MH161  114  61.3   34.3 
Meth178 173  56.9   40.2   
MH210  202  53.8   43.3   
MH17  241  68.8   46.3 
Meth134 349  59.2   47.6   
MC293  812  56.7   70.7  
MH428  540  69   80.3   
____________________________________________________________________ 
K562 cells were plated on 96 well plates at 1.5x104 cells/well. Twenty-Four hours later cells were pretreated with 
10µM of SB203580 (Calbiochem Co., USA). Three hours later mycelium crude extracts (see Table 4) were added 
at 1mg/ml and incubated for additional 24 hours. XTT assay was carried out as previously described. Growth 
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inhibition was calculated as before and relative to solvent-treated samples. The experiment was performed in 
duplicate with minimal variations.  
 
Effect of Mycelium Crude Extracts on the Expression of p210 
Bcr-Abl
  in k562 Cells 
Expression of p210 Bcr-Abl hybrid protein is correlated with carcinogenesis in CML. A number of CML 
inhibitors have been found to exert their effect by down-regulating the expression of p210 Bcr-Abl. We 
examined the ability of our mycelium crude extracts to affect p210 
Bcr-Abl
 expression levels. Fig. 3A 
and 3B demonstrate that exposure of K562 cells to AG957 (10µM and 20µM), Meth134 (500µg/ml 
and 250µg/ml), MH428 (500µg/ml and 250µg/ml), and MH17 (500µg/ml and 250µg/ml) caused a 
reduction in Bcr-Abl protein levels in K562 cells with varying potency. In contrast, no significant 
effect on p210 
Bcr-Abl
 levels was observed with use of  MH210, MC293, and Meth178 mycelium 
extracts. Interestingly, mycelium crude extract MH428 was the most potent of our selected  crude 
extracts and caused a dramatic reduction in both p210 Bcr-Abl and p145 c-Abl levels. However, the 








FIGURE 3. Effect of mycelium crude extracts on the expression of p210 Bcr-Abl  in K562 cells. 
 K562 cells were plated in T25 flasks at 1x105 cells /ml. Twenty-four hours later tyrphostin AG957, mushroom 
extracts MH210, Meth178, MH17 (part A), tyrphostin AG957, Meth134, MC293, and MH428 (part B) were 
added at 500µg/ml and 250µg/ml for 48 hr. Western Blotting was performed as described in Materials and 
Methods, in which monoclonal c-Abl antibody was used (Santa Cruz Co., USA). Filters were stripped and re-








CML is a malignancy of pluripotent hematopoietic cells characterized by the presence of the 
Philadelphia (Ph) chromosome, which results from reciprocal translocation between the long arms of 
chromosomes 9 and 22 {(t(9;22) q34;q11)} resulting in the creation of fusion gene p210 Bcr-Abl    with 
abnormal tyrosine kinase activity. The presence of active p210 Bcr-Abl renders CML cells resistant to 
apoptosis and delays differentiation.  
 
Medicinal mushrooms have been an important source of therapeutic substances for the treatment of 
various human diseases. Antitumor activities from mushrooms were described by many reports 
(Mizuno, 1999; Wasser, 2002). In most cases, activity was due to high-molecular-weight 
polysaccharides with a molecular weight of 200-400,000 Dalton. Antitumor activity of HMW 
polysaccharides was attributed to immune-modulation function or enhancement properties of the 
immune system, not as a result of direct influence on the tumor cells. In this study, we attempted to 
identify mycelium crude extracts that directly show antitumor effects against cancer cells. Furthermore, 
we used various organic mixtures to prepare our mycelium crude extracts in an attempt to enrich them 
with low molecular weight moieties that can easily penetrate the cell wall.  
 
Mycelium crude extracts prepared from our culture collection of Higher Basidiomycetes were 
evaluated for their ability to inhibit the growth of the  human chronic myelogenous leukemia cell line 
(K562 cell line) selectively. Using submerged conditions, we cultivated 42 species of Higher 
Basidiomycetes mushrooms and prepared 168 mycelium crude extracts by a variety of extraction 
methods. Initially, we evaluated the ability of our mycelium crude extracts to inhibit the growth of 
K562 cells by more than 50% compared with the solvent-treated cells. Data shown in Table 3 illustrate 
that 44 extracts were active in inhibiting K562 cells. However, only 8 were found to exhibit a selective 
effect against K562 cells. IC50 values for the K562-selective extracts ranged from 250 to 500 µg/ml.  
Most of the selective extracts showed partial or complete cytostatic activity and only MH161 showed 
cytotoxic activity against K562 cells (figure 1).  
 
The observed anti-proliferative activity of the selective K562 mycelium crude extracts was attributed to 
induction of apoptosis by most extracts, as determined by Apostain ELISA assay. Our results indicate 
that growth inhibition was caused by the induction of the apoptosis pathway and not as a result of 
necrosis. However, higher concentration or longer exposure time can also cause death from necrosis, as 
indicated by a reduction in DNA condensation determined by the Apostain ELISA assay (Table 5).  
Data obtained by monitoring PARP cleavage as an indication of apoptosis, illustrated that only our 
control AG957 and higher concentration of  MH428 could cause a significant cleavage of PARP, and 
not the other mycelium crude extracts. This might be explained by the fact that Apostain ELISA assay 
is a more sensitive measurement than the PARP cleavage assay. In addition, PARP cleavage assay 
measures a very late event in the apoptosis pathway, while Apostain measures a much earlier event. 





Characteristics of K562-Selective Mycelium Crude Extracts 
 
 
Above table summarized various characteristics of mycelium crude extracts obtained in this work. Positive activity 
is indicated by “+” and negative activity by “–“. The symbol  “++” and “+++” indicate greater potency of positive 
response. NT indicates not tested. 
 
K562 cells are pluripotent cells that are able to differentiate along a megakaryocytic, erythroid, or, to a 
lesser extent, monocytic lineage. Erythroid differentiation can be induced by a number of compounds 
including hemin and butyric acid (Villeval et al., 1983). K562 selective mycelium crude extracts were 
evaluated for their ability to induce erythroid differentiation in K562 cells. Three extracts, Meth178, 
MH17, and MH428 showed significant ability to induce hemoglobin production by a factor of 11.9, 
4.2, and 2.1, respectively. Interestingly, there was no correlation between the ability to induce 
apoptosis and to induce differentiation of the variety of mycelium crude extracts (Table 8). Mycelium 
crude extract Meth178 was the most potent in inducing erythroid differentiation. However, it was only 
a moderate inducer of apoptosis as determined by Apostain, and it failed to activate PARP cleavage. 
Conversely, MH428 extract showed weak activity in inducing erythroid differentiation, while it 
displayed the most significant apoptosis-inducing activity, as determined by both Apostain ELISA and 
PARP cleavage assays. Furthermore, mycelium extracts MC293 and Meth134 showed significant 
apoptosis activity as determined by Apostain ELISA assay, but failed to induce erythroid 
differentiation. Thus, the two activities are separable. At this stage, the molecular mechanism by which 
these mycelium extracts cause the induction of differentiation is not clear. It is worth noting that the 
hemoglobin produced in K562 is a fetal hemoglobin mainly γ-globin.  Increased expression of the 
endogenous γ-globin gene is a realistic approach to therapy of -globin disorders such as sickle cell 
anemia and -thalassemia  (Nagel et al., 1985; Labie et al., 1985). Thus, our mycelium extracts, 
especially Meth178, has the potential to serve as a therapy for -globin disorders.  
 
The fusion protein p210 Bcr-Abl play a principle role in CML carcinogenesis. Consequently, down-
regulation of p210 Bcr-Abl is an appealing strategy for developing chemotherapeutics for the treatment of 
CML. We evaluated the ability of our mycelium crude extracts to lower expression levels of p210 Bcr-
Abl
. Our data revealed that MH428 significantly inhibited the expression of p210 
Bcr-Abl
,  which was 
moderately inhibited by MH17. By contrast, the other extracts exerted a minor effect on the expression 
levels of p210 Bcr-Abl. The mechanism leading to down-regulation of p210 Bcr-Abl   by MH428 and MH17 
 MH428 MEth178 MH17 MH210 MC293 MEth134 MEth114 MH161 
Selective Growth 
Inhibition of K562 
cells 
+ + + + + + + + 
Down-regulation of 
Bcr-Abl 




+ +++ ++ - - - - - 
PARP cleavage + - - - - - NT NT 





Cytostatic Cytostatic Cytostatic   Cytostatic Cytostatic Cytotoxic 
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is unclear. However, it is worth investigating whether this down-regulation is caused by inhibition of 
the transcription of p210 Bcr-Abl   or by affecting protein degradation. A number of compounds such as 
geldanamycin and radicicol exhibited anti-proliferative effect against K562 cells, mediated in part by 
down-regulation of p210 Bcr-Abl  (Nimmanapalli et al., 2001; Shiotsu et al., 2000).  Immune-
precipitation analysis showed that p210Bcr-Abl formed multiple complexes with Hsp90, some containing 
p23 and others Hsp70.  Presence of geldanamycin (GA) decreased the association of p210Bcr-Abl  with 
Hsp90 and p23 and increased its association with the chaperones Hsp70 and p60Hop. Loss of 
Hsp90/p23 association and acquisition of Hsp70/p60Hop preceded GA-induced degradation of p210
Bcr-
Abl  (An et al., 2000).  Experiments are underway to investigate the possibility that MH428 mycelium 
extract regulates association of p210 Bcr-Abl   with the different HSP proteins and thereby affects its 
degradation. 
 
MAPK pathway includes the extra-cellular signal-regulated kinase (ERK), the c-Jun N-terminal kinase 
(JNK), and the p38 kinase modules (Cross et al., 2000). Such signaling pathways regulate multiple 
biological activities, including cell proliferation, differentiation, and survivals (Cobb, 1999). The bulk 
of the evidence suggests that activation of ERK pathway increases the cell death threshold (Ishikawa 
and Kitamura, 1999). Conversely, activation of the JNK and p38 kinase cascades is generally 
associated with enhanced activation of the apoptosis program (Ichijo et al., 1997). In an attempt to 
elucidate the mechanism of action of our mycelium crude extracts, we utilized potent and selective 
pharmacological inhibitors to investigate the role of p38 in mediating the anti-tumor effect of our 
mycelium crude extracts. Data shown in Table 7 argue that inhibition of MAPK p38 partially relieves 
growth inhibition caused by some mycelium crude extracts such as Meth178, MH17, Meth114, 
MH161, and MH210 but not by MC293 and MH428. This argues that MAPK p38 is not the principle 
mediator of the anti-proliferative function of our K562-selective mycelium crude extracts. Similar 
analysis using additional pharmaceuticals inhibitors targeting other second messenger pathways are 
required for the elucidation of the molecular pathways involved in mediating the anti-CML effect of 
our mycelium crude extracts. 
 
 
Data presented in this work illustrated the potential of MH428 extract as anti-CML therapy. This 
extract was prepared from Trametes zonata. Although there are no published reports showing 
biological activity or substances isolated from this mycelium, antitumor activity from related species 
has been reported (Hsieh and Wu, 2001).  A dietary supplement prepared from extracts of  Trametes 
versicolor are in use for general health purposes. Interestingly, ethanol extracts (70%) of T. versicolor 
dietary supplement reduced LNCaP cell growth and down-regulated the levels of secreted prostate 
specific antigen (PSA). This raises the possibility of chemopreventive potential for hormone-refractory 
prostate cancer (Hsieh and Wu, 2001).  Our results show that T. zonata extract has a therapeutic and 
chemopreventive potential for the treatment of CML. Interestingly, mycelium extracts of T. zonata that 
exhibited anti-proliferative activity against K562 cell line were also active against LNCaP cells (data 
not shown). These data indicate that like T. versicolor extract, T. zonata extract is active in inhibiting 
hormone-refractory prostate cancer cells. The need to investigate the effect of our extract on the 
function of androgen receptor (AR) and PSA expression and secretion still remains.  
 
Data presented here show the potential of medicinal higher Basidiomycetes mushrooms for the 
treatment of neoplastic diseases and -globin disorders. 
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